DBCG IMN2: IMNI OS HR 0.85, 15-yr survival 65.0% vs 60.8% in node-positive breast on modern systemic therapy; challenges node-count IMNI criteria.
Breast and prostate led. DBCG IMN2 (N=4541, 13.7yr f/u) confirms IMNI OS benefit in the modern systemic era, pushing back on node-count restrictions. PEACE V-STORM provides the first randomized signal for ENRT over MDT in pelvic nodal prostate recurrence (HR 0.62); phase 2 only. EORTC cutaneous lymphoma consensus adds guidance without trial data.
read the full digest →Studies · 38
- EORTC Cutaneous Lymphoma RT RecommendationsEORTC expert consensus on low-dose RT for all primary cutaneous lymphoma subtypes; no controlled trial data; retrospective evidence only.
- PEACE V-STORMPEACE V-STORM: 4-yr MFS 76% vs 63% favoring ENRT over MDT in pelvic nodal oligorecurrent prostate cancer, HR 0.62.
- DBCG IMN2DBCG IMN2: IMNI improved OS HR 0.85 (0.76–0.94), 15-yr survival 65.0% vs 60.8% in node-positive breast cancer on modern systemic therapy.
- CA Cancer Journal for Clinicians doi:10.3322/caac.70082CA Cancer J Clin 2026 paper (doi:10.3322/caac.70082): no extractable clinical content in source — PDF yielded only access/copyright boilerplate.
- SWOG S1007 RNI Analysis (Jagsi et al.)SWOG S1007 secondary analysis: RNI vs no RNI not associated with IDFS in RS≤25 N1 HR+/HER2-; 5-yr LRR <1% after BCS.
- Bladder Adjuvant Radiotherapy Phase III (Murthy et al.)Adj pelvic RT post-cystectomy improves 2-yr LRFS vs observation (87.1% vs 76.0%, HR 0.43, p=.04) in high-risk MIBC.
- Proton vs Photon PMRT Capsular ContractureProton PMRT trend toward higher CC vs photon (univariate HR 2.3, p=0.007); multivariable not significant (HR 1.76, p=0.083).
- LS-SCLC High-Dose Hyperfractionated RT (NCT03214003)54 Gy BID SIB vs 45 Gy BID in LS-SCLC: mOS 60.7 vs 39.5 mo, HR 0.55, p=0.003.
- Single-fraction SABR for primary NSCLC and pulmonary oligometastases (pooled analysis)SF-SABR (N=1687): LC 90-93% at 2yr, mOS 40mo (primary NSCLC) and 51mo (oligo), G3+ AEs 2.9%.
- ePLND vs PSMA PET staging for prostate cancer (AUA 2026 review)AUA 2026 review: PSMA PET NPV ~96%, no consistent RCT BCR benefit from ePLND; intermediate-risk pts may safely omit PLND if PET-negative.
- Bladder-preserving TMT for muscle-invasive bladder cancer (ESTRO 2026 multicenter analysis)CLR 63.7% in N=369 MIBC TMT cohort; 5-FU CRT and image guidance independently predict CLR on MVA.
- HEAT TrialHEAT interim: SBRT non-inferior to IMRT hypofractionation for biochemical control in localized PCa; BF 7% vs 7.4% at 4.25y.
- PEACE 2PEACE 2: pelvic RT did not improve cPFS (HR 0.81, p=0.088), MFS, OS, or PCSS vs prostate-only RT in very high-risk N0 PCa.
- TORPEdO (CRUK/18/010)TORPEdO (N=205): IMPT vs IMRT for OPSCC — UW-QoL physical composite null at 12 months; no HR-QoL difference at 3, 12, or 24 months.
- INRT-AIR & DARTBOARD pooled (ENI omission in HNSCC)Pooled INRT-AIR/DARTBOARD: 5-yr OS 87%, PFS 74%, 0% solitary elective nodal recurrence in 117 HNSCC pts.
- OPERA Trial (5-year)OPERA 5yr post-hoc: W14 clinical assessment identifies CR reliably; 5-yr OP 75% Arm A vs 83% Arm B (p=0.24), cCR/nCR OP equivalent.
- HCC EBRT Multinational IPD CohortLargest HCC EBRT IPD cohort (n=4,913): mOS 6.8yr BCLC-0, 4.6yr BCLC-A; outcomes comparable to resection and ablation.
- EXTEND TrialEXTEND phase II RCT: MDT+SOC (98% RT) improves PFS vs SOC in oligometastatic solid tumors, HR 0.54 (0.41-0.72), p<0.001, N=350.
- FASTRACK II (TROG 15.03)FASTRACK II: 100% local control at 84 months with SABR for primary RCC in 70 non-surgical pts (median f/u 62mo).
- NRG/RTOG 1005NRG/RTOG 1005: concurrent breast boost non-inferior to sequential for IBR (HR 1.31, 90% CI 0.84-2.04), 15 vs 22-31 total fractions.
- PIVOTALboostPIVOTALboost: focal boost + pelvic nodal RT (20 fx) safe at 2 yrs; no increase in late G2+ bowel/bladder toxicity vs prostate-only.
- PACE-NODESPACE-NODES: pelvic nodal SBRT feasible; acute GI G≥2 28% vs 21% (resolved by 12 wk); GU unchanged. Efficacy data pending.
- RADIOSAPost-hoc RADIOSA: median MFS 16.6mo vs NR, HR 0.39 favoring SBRT + 6mo ADT in oligorecurrent PCa.
- PEACE 2PEACE-2: pelvic RT adds no significant cPFS benefit over prostate-only RT in PSMA-staged very high-risk PCa (HR 0.81, p=0.09).
- PRIMEPRIME: G3+ tox <1% both arms; 5-fx SBRT vs mod hypo + whole-pelvis RT + ADT in high-risk/node-positive PCa; BFFS pending.
- OLIGOMAOLIGOMA: mPFS 35.8 vs 20.4mo (HR 0.48, p=0.021) favoring MDT in oligometastatic breast; QoL non-inferior.
- EORTC IM-MS (22922/10925)EORTC IM-MS 20yr: OS neutral HR 1.00, BCM reduction HR 0.82 offset by excess non-BCM deaths HR 1.26.
- HypoG-01HypoG-01 secondary analysis: LRR 16% of 118 events (20/118); failure patterns similar between 40 Gy/15 fx and 50 Gy/25 fx arms.
- DBCG HYPODBCG HYPO 10yr: 40Gy/15fr vs 50Gy, 10-yr induration 19.5% vs 24.7% (HR 0.76, p=0.005); no recurrence or survival difference.
- DBCG RT NaturalDBCG RT Natural: 4yr LR 1.5% (+RT) vs 9.8% (-RT) in low-risk ER+ BCS ≥60yr; stopped early per pre-specified 4% threshold.
- IMPORT HIGHIMPORT HIGH 10-yr: 48Gy/15F SIB IBTR 3.7% vs 3.5% (sequential boost); durable non-inferiority. 53Gy SIB 5.5%, not advantageous.
- Dutch Breast Boost (era of modern systemic therapy)10-yr IBTR 1.2% ± boost for 0-2 RF pts post-BCS (Dutch registry, N≈31k, 2012-2016): boost omission appears safe in modern systemic therapy era.
- RAPCHEMRAPCHEM 10-yr: nodal-response-guided locoregional RT de-escalation post-neoadjuvant yields <3% recurrence in breast cancer.
- APBI-IMRT FlorenceAPBI-IMRT Florence 15y: IBTR 7.7% vs 4.2% (HR 1.57, p=0.17); increase driven by new primaries, not true local relapse; no OS difference.
- EXTENDEXTEND: phase II randomized basket trial adding MDT to SOC in oligomets; primary JCO analysis out; no effect sizes in source tweet.
- OligoCareOligoCare (n=2447): SBRT achieves 88.6% LC at 3yrs in oligomets; CRC highest failure (19.6% at 3yrs).
- RCC SBRT 5-year local controlSBRT for primary RCC: tweet reports 100% (💯) local control at 5 years; no effect sizes or design details in source.
- DIREKHTDIREKHT: post-op HNSCC de-escalation trial testing contralateral neck sparing and 56 Gy primary CTV dose reduction; no outcome data in source.